In 2022, the World Health Organization reported that over 2 million newborns died within the first 20 days of life, while nearly 800 women died each day from preventable causes related to pregnancy and childbirth in 2020.
These statistics highlight the significant gap in maternal and infant healthcare, particularly in lower- and middle-income countries. To address this issue, Biorithm, a Singapore-based startup, has developed Femom, a device that allows women to monitor their pregnancies from home.
Femom works with a mobile application to transmit vital information, such as fetal heart rate, to healthcare professionals in real-time. The device is designed to be user-friendly and accessible to all women, regardless of their medical training.
By increasing access to essential health information, Biorithm aims to democratize pregnancy care and improve outcomes. The global market for medical devices is projected to grow significantly, presenting a promising opportunity for startups like Biorithm.
The company recently secured $3.5 million in funding to further develop Femom and expand its operations. Biorithm's innovative approach to pregnancy care reflects a broader movement towards empowering patients through technology.
By integrating technology into maternal care, Biorithm aims to reduce preventable deaths among mothers and newborns and improve overall healthcare outcomes.